Updated positive interim data showed notable improvements in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in control group in.
Reported revenues of $5.7 million in 4Q23, up 77% over prior year
Full year revenues of $18.5 million, up 49% over prior year
Gross Margin of 90% in 4Q23 and 86% for full year
CMS.
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Liberty University College of Osteopathic Medicine (LUCOM) Professor of immunology Dr. Christopher L. Kepley was awarded a three-year, $500,000 R15 grant from the National Cancer Institute in September, and now he is looking for Liberty students of all levels to join.
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript November 6, 2023 FibroGen, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.68. Operator: Hello and welcome to the FibroGen’s Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator […]